On Monday, June 21, 2021 from 4 – 5 pm ET, leading experts from the SITC Lymphoma Immunotherapy Guideline Expert Panel presented "SITC Clinical Practice Guideline Webinar – Practical Management Pearls for Immunotherapy for the Treatment of Lymphoma." This high-level webinar was designed so that...
2 attachments
On Wednesday, October 6, 2021 from 7–8 p.m. ET, join leading experts from the SITC Immune Checkpoint Inhibitor-related Adverse Events Guideline Expert Panel for the "SITC Clinical Practice Guideline Webinar – Case Studies in Immune Checkpoint Inhibitor-related Adverse Events." This high-level...
10-06-2021 | 19:00 - 20:00 ET
On Thursday, September 16, 2021 from 11:30 a.m.–12:30 p.m. ET, join leading experts from the SITC Immune Checkpoint Inhibitor-related Adverse Events Guideline Expert Panel for the "SITC Clinical Practice Guideline Webinar – Practical Management Pearls for Immune Checkpoint Inhibitor-related...
09-16-2021 | 11:30 - 12:30 ET
On Friday, August 13, 2021 from 10–11 a.m. ET, join leading experts from the SITC Immune Checkpoint Inhibitor-related Adverse Events Guideline Expert Panel for the "SITC Clinical Practice Guideline Webinar – Immune Checkpoint Inhibitor-related Adverse Events." This webinar is designed as an...
08-13-2021 | 10:00 - 11:00 ET
The recent development and clinical implementation of novel immunotherapies for the treatment of Hodgkin and non-Hodgkin lymphoma have improved patient outcomes across subgroups. The rapid introduction of immunotherapeutic agents into the clinic, however, has presented significant questions...
Combining inhibitors of vascular endothelial growth factor and the programmed cell death protein 1 (PD1) pathway has shown efficacy in multiple cancers, but the disease-specific and agent-specific mechanisms of benefit remain unclear. The authors examined the efficacy and defined the mechanisms...
Colitis is one of the common immune-related adverse events that leads to morbidity and treatment discontinuation of immunotherapy. The clinical presentation, endoscopic and histopathological features and best management of this toxicity are not well defined. The authors conclude that clinically...
The authors have aimed to assess the impact of genomic human leukocyte antigen (HLA)-I/II homozygosity on the survival benefit of patients with unresectable locally advanced, metastatic non-small lung cancer treated by single-agent programmed cell death protein-1/programmed death ligand 1 (PD1...
Recent research suggests that baseline body mass index (BMI) is associated with response to immunotherapy. In this study, the authors tested the hypothesis that worsening nutritional status prior to the start of immunotherapy, rather than baseline BMI, negatively impacts immunotherapy response....
To evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of eftilagimod alpha (efti), a soluble lymphocyte activation gene-3 protein, in combination with the programmed cell death-1 (PD-1) antagonist pembrolizumab. The authors conclude that efti was well tolerated in...
Join
Renew
Member Directory
My Profile
Email Sign-up
Volunteer
Support SITC
Contact Us